Personalis (Tempus)

Maker of the ultra-sensitive NeXT Personal MRD test, being acquired by Tempus AI for about $1.5B (announced July 2026).

NeXT Personal is a tumour-informed whole-genome MRD assay; clinical volumes grew 33% quarter over quarter to 10,384 tests in Q2 2026. Tempus agreed to acquire Personalis at $16.25 per share in stock, closing expected late 2026 or early 2027.

Headquarters